# Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

> **NCT03049852** · PHASE2 · COMPLETED · sponsor: **Cloudbreak Therapeutics, LLC** · enrollment: 75 (actual)

## Conditions studied

- Pterygium

## Interventions

- **DRUG:** CBT-001 single dose
- **DRUG:** Vehicle
- **DRUG:** CBT-001 Multi-dose

## Key facts

- **NCT ID:** NCT03049852
- **Lead sponsor:** Cloudbreak Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-15
- **Primary completion:** 2018-04-30
- **Final completion:** 2018-04-30
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2020-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03049852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03049852, "Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03049852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*